Clinical trial
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
NCT00112073 · JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT00112073 |
|---|---|
| Title | AAB-001 in Patients With Mild to Moderate Alzheimer's Disease |
| Official title | A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD |
| Lead sponsor | JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug, Other |
| Interventions | bapineuzumab, placebo |
| Enrollment | 234 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 30, 2005 |
| Last update posted | Mar 14, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: